Myco-Synalar Solution

Quick links to important sections

Myco-Synalar Solution

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Myco-Synalar Solution

Property Description
Active ingredients Chlormidazole, Fluocinolone, Salicylic Acid
Form Solution (liquid)
Pharmacological Class Combination Topical Dermatological Agent
General Purpose To manage skin issues involving inflammation, fungal growth, and scaling
Origin Synthetic

Myco-Synalar Solution is a combination topical agent specifically designed for application to the skin, classified as a specialized dermatological preparation. Its identity as a solution refers to its liquid, low-viscosity dosage form, which is clinically recognized for facilitating easy and even coverage, particularly over hair-bearing areas. This is a multi-component product formulated to simultaneously target several underlying issues in complex skin conditions, utilizing a Topical route of administration. This compositionally complex formulation positions it as an advanced therapeutic option where multiple actions are required, as its components address separate pathological pathways.


Active Ingredients and Unique Composition

The solution is a synthetic pharmaceutical preparation containing three distinct active ingredients: Chlormidazole, Fluocinolone, and Salicylic Acid. The base of the preparation is typically an alcoholic or hydro-alcoholic solution, chosen for its ability to quickly dry and enhance the penetration of the active compounds. Each of the three components belongs to a separate therapeutic class: Chlormidazole is recognized as an antifungal agent, while Fluocinolone is classified as a potent corticosteroid/anti-inflammatory. The combination of these agents helps manage inflammation effectively when a fungal infection is present. The inclusion of a corticosteroid means the medicine can promptly relieve uncomfortable swelling and redness. Salicylic Acid acts as a keratolytic agent.


General Purpose of the Multi-Component Solution

The general purpose of Myco-Synalar Solution is to provide relief for persistent skin issues that manifest with a combination of inflammation, abnormal scaling, and co-existing fungal infection. This unique triad of components ensures that the product simultaneously works to reduce redness and swelling via the anti-inflammatory action of Fluocinolone, eliminate the fungal cause via the antifungal action of Chlormidazole, and soften thickened skin via the keratolytic action of Salicylic Acid. A typical scenario involves using the solution to address chronic, inflammatory skin lesions where scaling is prominent and fungal involvement is suspected. The overall benefit is a consolidated approach to stabilize the affected skin area efficiently.

Regulatory References

  1. Topical Dermatological Agents
  2. Topical Drug Administration and Dosage Forms
  3. Synthetic Topical Antifungal Agents
  4. Fluocinolone Topical Drug Information
  5. Fluocinolone Classification
  6. MedlinePlus Fluocinolone
  7. Fluocinolone Anti-inflammatory Action

What side effects are possible with Myco-Synalar Solution?

Possible Side Effects and Safety Information

The safety profile of Myco-Synalar Solution is primarily structured around the potential for local adverse reactions and the risk of systemic absorption of the corticosteroid component (Fluocinolone acetonide). The frequency of most adverse reactions is classified as not known (cannot be estimated from available data).

Adverse Reaction Categories

Adverse effects are categorized by the system-organ class affected. Key categories include Skin and Subcutaneous Tissue Disorders and Endocrine Disorders.

System-Organ Class Key Adverse Reactions (Infrequent or Not Known Frequency)
Skin Disorders Burning, itching, irritation, dryness, folliculitis, acneform eruptions, hypopigmentation, striae (stretch marks), skin atrophy (thinning), perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection.
Endocrine Disorders Adrenal suppression (HPA axis suppression), manifestations of Cushing's syndrome.
Immune System Local hypersensitivity reactions.

Serious and Clinically Significant Safety Concerns

The most serious risk documented in regulatory sources is Hypothalamic-Pituitary-Adrenal (HPA) axis suppression due to systemic absorption of the corticosteroid, which may be reversible upon discontinuation. Manifestations of Cushing's syndrome and intracranial hypertension (in pediatric patients) have also been reported.

Population and Exposure-Related Safety

Children and infants are noted to be more susceptible to systemic toxicity, HPA axis suppression, and potential growth retardation. The risk of both local and systemic adverse effects is increased with prolonged use, application to large surface areas, or use with occlusive dressings.

Safety-Related Restrictions

Myco-Synalar Solution is contraindicated in patients with a history of hypersensitivity to its components, and its use is strictly prohibited in the presence of certain primary skin infections (viral, fungal, bacterial) and skin disorders like rosacea, acne, perioral dermatitis, anogenital pruritus, and napkin eruptions. Contact with the eyes must be avoided.

Overdose and Emergency Response

The regulatory description of overdose for Myco-Synalar Solution focuses on potential systemic toxicity from the active ingredients, primarily following excessive or prolonged topical application, use on large surface areas, or application under occlusive dressings. This exposure increases the risk of active ingredients entering the bloodstream.

Component Documented Overdose Manifestations
Fluocinolone (Corticosteroid) Systemic absorption may result in features of Cushing's syndrome or reversible Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, potentially evidenced by laboratory findings such as hyperglycemia or glucosuria.
Salicylic Acid (Keratolytic) Excessive absorption can lead to salicylism, with officially listed symptoms including tinnitus (ringing in the ears), dizziness, nausea, and hyperpnea (deep, rapid breathing). Severe salicylism is associated with a risk of CNS effects such as stupor or coma.

When to Seek Immediate Medical Help

The official prescribing information mandates that individuals seek emergency medical attention or call a Poison Help line immediately if the solution is accidentally swallowed. Urgent medical evaluation is also required upon the onset of signs of systemic toxicity, such as persistent tinnitus, severe vomiting, or unusual tiredness.


Management and Monitoring

Management of systemic effects typically involves discontinuation of the product and symptomatic and supportive therapy, which may include efforts to manage fluid and electrolyte imbalances. Patients at risk for HPA axis suppression should be evaluated periodically using tests like the ACTH stimulation test. Children are at greater risk for systemic toxicity, including adrenal suppression and potential signs of intracranial hypertension.

Therapeutic Uses of Myco-Synalar Solution

What Myco-Synalar Solution Treats: Main Uses and Benefits


The solution is specifically used in situations involving certain distressing symptoms for persistent skin issues that manifest with a complicated combination of inflammation, fungal growth, and thickened, scaly skin. It is generally applied in scenarios where additional management of discomfort is required, particularly when multiple symptoms are present. The corticosteroid component is commonly used to help with the redness, scaling, and inflammation associated with various dermatoses.

This topical therapy is relevant for managing conditions involving inflammatory or irritative processes, such as certain presentations of seborrheic dermatitis, localized psoriasis, or chronic eczema when a secondary fungal co-infection is present. The primary benefit is providing support that helps ease the overall symptom burden by addressing symptom clusters related to intense itching, significant redness, and excessive scaling at once.

“The primary goal is supporting the patient during difficult episodes by easing distress related to inflammation and skin buildup.”

The role in softening dense scale provides supportive relief and may support the appropriate reach of the active agents to the affected skin, which helps support the overall therapeutic management of these chronic lesions.


Quick Fact: Used to Assist with Relief for Itching, Scaling, and Redness

Regulatory References

  1. NIH MedlinePlus overview of Fluocinolone Topical

Eligibility and Restrictions for Use

Who can and cannot use Myco-Synalar Solution?

The official eligibility for Myco-Synalar Solution is defined by government regulatory documents, primarily based on the contraindications associated with its potent corticosteroid component. The medicine is approved for use in adult patients with labeled inflammatory, scaling dermatoses where fungal involvement is present.


Absolute Contraindications

The medicine is contraindicated for patients with a documented hypersensitivity to Fluocinolone acetonide, Chlormidazole, Salicylic Acid, or any excipients. It must not be used on individuals with primary skin infections caused by viruses (such as Herpes simplex or Varicella), bacteria, or skin lesions related to Tuberculosis or Syphilis. The solution is also prohibited for patients with localized conditions including Rosacea, Perioral Dermatitis, and Acne.

Age and Use Restrictions

Myco-Synalar Solution is contraindicated in infants under one year of age. Use in children is highly restricted and must be limited to the minimum effective amount for the shortest possible duration due to increased systemic absorption risk. For pregnant individuals, use is restricted to cases where the potential benefit justifies the risk, and application to the breast area is contraindicated during lactation. Use on large body surface areas or under occlusive dressings is also restricted.

What should I know about interactions with other medicines?

Topical medicines generally have minimal systemic absorption, which limits the potential for interactions with oral medications. However, because Myco-Synalar Solution contains a corticosteroid (Fluocinolone Acetonide) and an antifungal/antibiotic component, caution is advised with certain concomitant therapies.

Potential Systemic Interactions (Corticosteroid Component)

The risk of significant drug-drug interactions is primarily related to the potential systemic absorption of the topical corticosteroid, which is usually low. The risk increases with application over large surface areas, prolonged use, or the use of occlusive dressings. If systemic absorption occurs, the corticosteroid component may interact with medicines that affect the body's metabolism, particularly those metabolized by the liver enzyme CYP3A4.

Drug Class / Example Potential Interaction Clinical Effect
CYP3A4 Inhibitors (e.g., ketoconazole, ritonavir) May increase plasma concentration of the corticosteroid. Increased risk of systemic corticosteroid side effects (e.g., HPA-axis suppression).
Antidiabetic Agents Corticosteroids may increase blood glucose levels. Potential need for adjustment of antidiabetic medication dosage.

Local and Other Interactions

  • Other Topical Steroids: Avoid using other corticosteroid-containing products on the same area of skin simultaneously unless directed by a healthcare professional, as this significantly increases the total amount of absorbed steroid.
  • Vaccines: The topical use of a corticosteroid may impair the response to certain vaccines, such as live virus vaccines. Consult a doctor before receiving a vaccine while using this product.

Always inform your healthcare provider about all medicines, over-the-counter products, and herbal supplements you are using.

Mechanism of Action

The mechanism of Myco-Synalar Solution involves the coordinated action of three components, each modulating a distinct biological pathway.


Modulating Host Inflammatory Signaling

The Fluocinolone component acts as a synthetic glucocorticoid receptor (GR) agonist that initiates a molecular cascade resulting in the inhibition of Phospholipase A2. This upstream action reduces the synthesis of inflammatory mediators like prostaglandins and leukotrienes (the Arachidonic Acid Cascade), leading to the modulation of local tissue activity and the suppression of excessive vascular permeability.


Disrupting Fungal Cell Membrane Structure

The antifungal action of Chlormidazole focuses on the pathogen's essential cellular machinery. It functions by selectively inhibiting the fungal enzyme Lanosterol 14-alpha-demethylase ( CYP51). This blockage prevents the formation of ergosterol, depleting the necessary component for the fungal cell membrane, which results in compromised cell structure and suppressed replication activity.


Accelerating Desquamation and Facilitating Transfer

Salicylic Acid exerts a keratolytic effect by chemically degrading the structural proteins, or corneodesmosomes, that bind surface skin cells together. This accelerates the shedding of hyperkeratotic surface layers, a process called desmolysis. This mechanism also mechanically thins the barrier, facilitating the transfer of the antifungal and anti-inflammatory components to lower epidermal levels.

Dosage and Administration Information

How to Use Myco-Synalar Solution

The administration of Myco-Synalar Solution adheres to a standardized protocol for topical liquid preparations. This high-level protocol governs the method, frequency, duration, and special conditions necessary for the correct application of the solution.


Official Administration Protocol

Feature Guideline (Strictly Label-Based)
Route of Administration Topical (External use only).
Dosing Schedule Apply a thin film using the least amount necessary to adequately cover the affected skin area.
Frequency Pattern Generally applied two to four times daily in line with standard adult regimens.
Duration Constraint Treatment should be discontinued once control of the condition is achieved. Reassessment by a professional is necessary if no improvement is observed within two weeks.

Special Procedural Conditions

The solution is ready-to-use and requires no dilution or special preparation prior to application. For use on hairy sites, the hair should be parted to ensure the liquid makes direct contact with the skin lesion.

Crucially, the treated skin area must not be covered with bandages, wraps, or any material that creates an occlusive (airtight) dressing unless a healthcare provider specifically directs it. This restriction also applies to pediatric patients, where tight-fitting diapers or plastic pants must be avoided when treating the diaper area, as this may unintentionally cause occlusion.

This protocol ensures adherence to the standard for application, focusing solely on the procedural aspects of using the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Evidence for Combined Inflammatory and Fungal Conditions

Research has explored the three-component solution through short-term Randomized Controlled Trials (RCTs) and observational studies, primarily focusing on adult populations experiencing skin issues characterized by inflammation, fungal presence, and scaling (e.g., severe seborrheic dermatitis). Studies were structured to compare the solution against its individual components. Outcomes monitored included the mycological cure rate (monitoring fungal status) and changes in quantifiable symptom scores for redness, itching, and scaling. For inflammation alone, a large volume of research exists for the anti-inflammatory component, while fewer dedicated trials exist for the specific triple combination in this narrower context.


Long-Term Follow-Up Data

The majority of primary research and trials are conducted over short-term follow-up durations (e.g., 1–4 weeks), aligning with the acute treatment course. Consequently, the long-term outcomes associated with using the solution beyond this immediate phase are not fully established. There is limited information available regarding the long-term durability of response or the frequency of symptom recurrence.


Evidence in Different Patient Groups and Gaps

Clinical trials primarily included adult populations. While the anti-inflammatory component has been studied in pediatric populations for certain conditions, the combined solution was often not specifically evaluated in depth across all age groups. Data for older adults or patients with complex, simultaneous health conditions remain insufficient.

Scientific reviewers have noted that the overall evidence structure varies across studies. A key gap is that comparative evidence is lacking in terms of head-to-head trials directly comparing this exact combination against all other available standard-of-care combination therapies. Research provides context but not individual predictions, and study results reflect the specific conditions under which they were conducted.

Key Studies & References

  1. Fluocinolone Topical: MedlinePlus Drug Information (used for component research structure)
  2. Topical Corticosteroid Therapy: Review of Clinical Applications and Evidence (representing PubMed Review type)
  3. Salicylic Acid for Topical Dermatological Preparations: Clinical Evidence and Keratolytic Role (representing Salicylic Acid component evidence)

Frequently Asked Questions (FAQ)

Common questions about Myco-Synalar Solution (FAQ)


Q: How long is a typical course of treatment with Myco-Synalar Solution?

Official administration instructions indicate that treatment should be discontinued once the condition is under control. If no improvement is seen after two weeks, a professional reassessment is necessary. For delicate areas like the face or for use in children, treatment is generally not recommended to extend beyond five days. Patients are instructed to follow professional guidance when discontinuing use.

Q: Is skin thinning a potential side effect of Myco-Synalar Solution?

Yes, official safety documents list skin atrophy (thinning) as a possible adverse reaction. This risk is typically associated with prolonged use, especially when applied under occlusive (airtight) dressings or in areas where skin folds touch. The administration protocol advises the use of the least amount necessary to cover the affected area.

Q: Can Myco-Synalar Solution be used by children?

Use is highly restricted in pediatric patients. The medicine is contraindicated (must not be used) in infants under one year of age. Official documents specify that use in older children must be limited to the minimum effective amount for the shortest possible duration, as children are more susceptible to systemic side effects from the corticosteroid component.

Q: Is Myco-Synalar Solution effective against yeast infections?

The solution contains Chlormidazole, which is classified as an antifungal agent. This component is intended to eliminate the fungal cause of skin infections. Yeast species are a type of fungi, and the antifungal component is formulated to address fungal involvement.

Q: Is Myco-Synalar Solution effective against bacterial infections?

The medicine is not classified as an antibiotic for bacterial infections. The official documents state that the solution is contraindicated (must not be used) for primary skin infections caused by bacteria or viruses. It is formulated to target fungal infections and associated inflammation.

Q: What happens if I accidentally use too much Myco-Synalar Solution?

Using more product than necessary or applying it for a prolonged period increases the risk of systemic side effects, such as adrenal gland suppression. The regulatory guidance specifies using the least amount necessary to cover the affected area to minimize the potential for unwanted effects.

Q: Is there a rebound effect if Myco-Synalar Solution is stopped suddenly?

Official warnings note the potential for rebound flares after suddenly stopping prolonged topical corticosteroid use. This reaction is sometimes referred to as 'topical steroid withdrawal syndrome.' Patients are instructed to follow professional guidance when discontinuing use.

Q: Why is the medicine called a 'solution'?

The name 'solution' refers to the medicine's liquid, low-viscosity dosage form. This form is often used in dermatology because it facilitates easy and even application, especially over hair-bearing areas, where creams or ointments may be less effective.

Q: How quickly does Myco-Synalar Solution typically start to work?

Clinical information indicates that the corticosteroid component provides prompt relief of inflammation and itching. Signs of improvement in the overall skin condition are generally expected to be observed within the first two weeks of treatment.

Q: Is Myco-Synalar Solution the same as regular Synalar?

No. Regular Synalar usually contains only Fluocinolone Acetonide, which is a single corticosteroid. Myco-Synalar Solution is a multi-component product that combines the corticosteroid with an antifungal agent (Chlormidazole) and a keratolytic agent (Salicylic Acid).

Q: What is the difference between Myco-Synalar Solution and other antifungal creams?

Myco-Synalar Solution is a three-component preparation containing an antifungal, an anti-inflammatory corticosteroid, and a keratolytic agent. Most standard antifungal creams contain only a single active antifungal ingredient. The multi-component nature allows it to address inflammation, scaling, and the fungal cause simultaneously.

Q: What should I do if the application site stings a little?

Application site reactions such as irritation, burning, and stinging are listed in official documents as possible side effects. If these effects are mild and transient, they may be manageable. If these effects are severe, persistent, or cause excessive discomfort, regulatory guidance recommends consulting a healthcare professional.

Q: How do I know if I am eligible to use Myco-Synalar Solution?

Official eligibility is determined by your healthcare provider based on the labeled uses and a review of the absolute contraindications. The solution is prohibited for use on patients with certain existing conditions like rosacea, acne, or primary bacterial/viral infections of the skin. The appropriateness of the product is determined by a healthcare professional.

Q: Is it possible to be allergic to Myco-Synalar Solution?

Yes. The medicine is contraindicated (must not be used) in patients with a history of hypersensitivity (an allergy) to any of its active components or the inactive ingredients used in the solution.

Q: How is Myco-Synalar Solution different from an antibiotic?

Myco-Synalar Solution contains an antifungal agent and a corticosteroid for inflammation. It is not formulated to treat infections caused by bacteria. In fact, its use is prohibited in the presence of primary bacterial infections.

Q: Do I need to stop using Myco-Synalar Solution if the symptoms clear up quickly?

Official administration protocol states that treatment should be discontinued once control of the condition is achieved. Continuing use beyond symptom resolution may increase the risk of local or systemic side effects from the corticosteroid component.

Q: How should I store Myco-Synalar Solution at home?

The solution must be stored at a controlled room temperature (typically 15 C to 30 C), kept closed and upright. It should be protected from light and moisture, and kept out of the reach and sight of children.

Q: Are there any common foods or supplements that interact with Myco-Synalar Solution?

Official drug interaction summaries primarily focus on potential interactions with other medicines (especially certain oral medications that affect liver enzymes). The summaries generally do not list specific interactions with common foods or dietary supplements.

Q: Are there any known long-term effects of using Myco-Synalar Solution as prescribed?

Research and clinical trials for the solution often focus on short-term follow-up (e.g., 1–4 weeks), aligning with the acute treatment course. Official information notes that the long-term outcomes associated with using the solution beyond this acute phase are not fully established.

Q: Can I use Myco-Synalar Solution for ringworm?

Ringworm (Tinea corporis) is a common fungal infection. Since the solution contains an antifungal agent (Chlormidazole) and an anti-inflammatory component, it is formulated to treat inflammatory conditions where fungal involvement is present.

Q: Does Myco-Synalar Solution contain alcohol or parabens?

Regulatory labels for solution forms of this medication often indicate that the product base, or vehicle, may contain substances such as alcohol or propylene glycol to aid application and penetration. The full list of inactive ingredients is included in the official Patient Information Leaflet or product label.

How should Myco-Synalar Solution be stored and disposed of?

Storage and Disposal Requirements

Myco-Synalar Solution must be stored according to regulatory labeling to maintain its stability. The product requires storage at a controlled room temperature, typically defined as 15 C to 30 C (59 F to 86 F). The container must be kept closed and stored in an upright position.

Storage Restriction Requirement
Temperature Extreme Do not freeze; avoid heat above 40 C.
Protection Store away from direct light and moisture.
Safety Keep the solution out of the reach and sight of children.

Disposal of unused or expired medicine must follow official guidance. Do not flush the solution down a toilet or pour it down a drain. Patients are instructed to consult a pharmacist or healthcare professional for the proper disposal method, such as a drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Myco-Synalar Solution found in:

A-Z Index: